Celgene Corporation (CELG): Today's Featured Drugs Winner
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Celgene Corporation rose $4.66 (3.4%) to $140.65 on average volume. Throughout the day, 3,030,219 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,010,600 shares. The stock ranged in a price between $135.81-$140.79 after having opened the day at $139.02 as compared to the previous trading day's close of $135.99. Other companies within the Drugs industry that increased today were:
(
), up 15.2%,
(
), up 11.6%,
(
), up 9.0% and
(
), up 7.8%.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $56.3 billion and is part of the health care sector. Shares are up 72.1% year to date as of the close of trading on Wednesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Celgene Corporation
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Celgene Corporation Ratings Report.
On the negative front,
(
), down 29.6%,
(
), down 20.9%,
(
), down 14.2% and
IntelliPharmaCeutics International
(
), down 13.0% , were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null